# Special Issue

# Novel Therapeutic Targets and Management in Pediatric Cancer

# Message from the Guest Editor

The treatment of pediatric malignancies has reached a milestone in recent years. The wide use of modern diagnostic methods provides a deeper insight into the molecular background of pediatric solid tumors and leukemias, which facilitates a better prognostic estimation for individual tumors and also enables the use of targeted therapy in certain cases. The introduction of treatment modalities applying immunological aspects of leukemias and solid tumor provides the long-term control of tumor growth and a better survival. Newer approaches of targeted and immunotherapy will hopefully fundamentally change the treatment of pediatric malignancies by the marginalization of conventional chemotherapy with an increased burden of long-term side effects. The application of modern molecular technics may promote the early recognition of predisposition syndromes, patients then undergoing a subsequent regular followup, helping an early diagnosis and better survival of pediatric malignancies in certain cases. This SI aims to provide an overview of the recent advances in predisposition syndromes, targeted treatment, and immunotherapy in the field of pediatric hematology and oncology.

### **Guest Editor**

Dr. Péter Hauser

Department of Pediatrics, Borsod-Abaúj-Zemplén County Central Hospital and University Teaching Hospital, Budapest, Hungary

# Deadline for manuscript submissions

closed (20 December 2024)



# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/176779

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com\_

mdpi.com/journal/ cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Author Benefits**

# **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

